Literature DB >> 10229232

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

R R French1, H T Chan, A L Tutt, M J Glennie.   

Abstract

CD40 is essential in enabling antigen-presenting cells to process and present antigen effectively to T cells. We demonstrate here that when antibody against CD40 is used to treat mice with syngeneic lymphoma, a rapid cytotoxic T-cell response independent of T-helper cells occurs, with tenfold expansion of CD8+ T cells over a period of 5 days. This response eradicates the lymphoma and provides protection against tumor rechallenge without further antibody treatment. Thus, it seems that by treating mice with monoclonal antibody against CD40, we are immunizing against syngeneic tumors. The phenomenon proved reproducible with two antibodies against CD40 (3/23 and FGK-45) in three CD40+ lymphomas (A20, A31 and BCL1) and gave partial protection in one of two CD40- lymphomas (EL4 and Ten1). Although the nature of the target antigens on these lymphomas is unknown, CD8+ T cells recovered from responding mice showed powerful cytotoxic activity against the target B-cell lymphoma in vitro.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229232     DOI: 10.1038/8426

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  130 in total

1.  New developments in autologous tumor cell vaccination therapy for renal cell carcinoma.

Authors:  A J van den Eertwegh ; H M Pinedo
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

Review 2.  Biotherapy for lymphoma.

Authors:  P McLaughlin
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.075

3.  Short-circuiting long-lived humoral immunity by the heightened engagement of CD40.

Authors:  Loren D Erickson; Brigit G Durell; Laura A Vogel; Brian P O'Connor; Marilia Cascalho; Teruhito Yasui; Hitoshi Kikutani; Randolph J Noelle
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

4.  A potent adjuvant effect of CD40 antibody attached to antigen.

Authors:  Tom A Barr; Adele L McCormick; Jennifer Carlring; Andrew W Heath
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

5.  Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus.

Authors:  Roman A Tuma; Rielle Giannino; Patrick Guirnalda; Ingrid Leiner; Eric G Pamer
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

6.  Systemic treatment with anti-CD40 antibody stimulates Langerhans cell migration from the skin.

Authors:  S Jolles; J Christensen; M Holman; G B Klaus; A Ager
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

7.  Co-administration of CD40 agonistic antibody and antigen fails to overcome the induction of oral tolerance.

Authors:  Yeonseok Chung; Dong-Hyeon Kim; Seung-Ho Lee; Chang-Yuil Kang
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

8.  A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.

Authors:  Jeffrey D Ahlers; Igor M Belyakov; Masaki Terabe; Rima Koka; Debra D Donaldson; Elaine K Thomas; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

9.  Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.

Authors:  Fubin Li; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

Review 10.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.